AMGN stock page - price, fundamentals, dividends - iOCharts

AMGN

244.68
-0.40 (-0.16%)
Amgen Inc (NASDAQ, USD)
Healthcare >
Drug Manufacturers-General
Market cap
140.58B
Ent value
187.67B
Price/Sales
5.53
Price/Book
15.06
Div yield
2.88%
Div growth
15.16%
Growth years
11
FCF payout
39.16%
Trailing P/E
19.35
Forward P/E
13.75
PEG
2.82
EPS growth
14.00%
1 year return
-3.54%
3 year return
8.22%
5 year return
8.00%
10 year return
16.00%
Last updated: 2021-07-28

STOCK INFORMATION

Stock chart
Loading...
Stock price data
All-time high260.95
1y analyst estimate256.88
Beta0.71
EPS (TTM)12.56
Dividend per share7.04
Ex-div date14 May 2021
Next earnings date3 Aug 2021
Downside potential
Loading...
Downside potential data
AMGNS&P500
Current price drop from All-time high-6.23%-0.46%
Highest price drop-60.17%-56.47%
Date of highest drop15 Jul 20029 Mar 2009
Avg drop from high-17.96%-11.53%
Avg time to new high23 days13 days
Max time to new high1773 days1805 days

DIVIDENDS

Dividend yield - 5y
Loading...
Dividend yield data
Dividend per share7.04
Dividend yield2.88%
Payout frequencyQuarterly
Maximum yield3.51%
Average yield2.84%
Minimum yield2.28%
Discount to avg yield1.14%
Upside potential1.15%
Yield as % of max yield81.93%
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
Dividend yield2.88%
Current yield distribution43.17%
Yield at 100% (Min)2.28%
Yield at 90%2.54%
Yield at 80%2.65%
Yield at 50% (Median)2.84%
Yield at 20%3.05%
Yield at 10%3.14%
Yield at 0% (Max)3.51%
Dividend per share
Loading...
Dividend per share data
Years of growth11 years
CCC statusDividend Contender
Dividend per share7.04
Payout frequencyQuarterly
Ex-div date14 May 2021
EPS (TTM)12.56
EPS (1y forward)17.80
EPS growth (5y)14.00%
EPS growth (5y forward)6.87%
Dividend growth
Loading...

Please create a free account or log in to access this chart

Dividend growth data
AMGNS&P500
DGR MR10.00%7.68%
DGR TTM10.16%-2.66%
DGR 3 years11.64%5.82%
DGR 5 years15.16%6.23%
DGR 10 years-9.64%
DGR 15 years-6.71%
Time since last change announced229 days
EPS growth (5y)14.00%
EPS growth (5y forward)6.87%
Payout ratio
Loading...

Please create a free account or log in to access this chart

Payout ratio data
EPS coverageFCF coverage
TTM51.69%39.16%
Average--
Forward39.55%-

FINANCIALS

Per share
Loading...
Per share data
Current share count574.55M
EPS (TTM)12.56
FCF per share (TTM)16.58
Income statement
Loading...
Income statement data
Revenue (TTM)25.42B
Gross profit (TTM)19.27B
Operating income (TTM)9.14B
Net income (TTM)7.26B
EPS (TTM)12.56
EPS (1y forward)17.80
Margins
Loading...
Margins data
Gross margin (TTM)75.77%
Operating margin (TTM)35.95%
Profit margin (TTM)28.57%
Balance Sheet
Loading...

Please create a free account or log in to access this chart

Balance Sheet data
Cash6.11B
Net receivables4.42B
Total current assets21.30B
Goodwill14.67B
Intangible assets15.95B
Property, plant and equipment4.86B
Total assets62.54B
Accounts payable11.31B
Short/Current long term debt32.69B
Total current liabilities12.87B
Total liabilities53.20B
Shareholder's equity9.33B
Net tangible assets-21.29B
Cash flow
Loading...

Please create a free account or log in to access this chart

Cash flow data
Operating cash flow (TTM)10.50B
Capital expenditures (TTM)908.00M
Free cash flow (TTM)9.59B
Dividends paid (TTM)3.75B
Financial returns
Loading...

Please create a free account or log in to access this chart

Financial returns data
Return on Equity77.20%
Return on Assets11.54%
Return on Invested Capital17.13%
Cash Return on Invested Capital22.62%
COMPANY DETAILS
AMGN (Amgen Inc) company logo
Marketcap
140.58B
Marketcap category
Large-cap
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. It also has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Employees
24300
Investor relations
SEC filings
CEO
Robert Bradway
Country
USA
City
Thousand Oaks
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Loading...